Hornby, Brittany
Thompson, William Reid
Almuqbil, Mohammed
Manuel, Ryan
Abbruscato, Anthony
Carr, Jim
Vernon, Hilary J. http://orcid.org/0000-0001-9940-9866
Article History
Received: 26 November 2021
Accepted: 13 August 2022
First Online: 2 September 2022
Declarations
:
: The TAZPOWER trial was approved under the Johns Hopkins Institutional Review Board Protocol IRB00124162 and the NHC study was approved under the Johns Hopkins Institutional Review Board Protocol IRB00231209. The trials were conducted in accordance with consensus ethics principles derived from international ethics guidelines, including the Council for International Organizations of Medical Sciences International Ethical Guidelines and the International Conference on Harmonisation Good Clinical Practice guideline. The protocol was approved by the institutional review boards of the participating trial centers and all patients provided written informed consent.
: Not applicable.
: AA and JC are employees of Stealth BioTherapeutics, Needham, MA. HJV received clinical trial and research funding from Stealth BioTherapeutics, Needham, MA.